United States Undescended Testicle Market Size & Outlook, 2026-2034
United States Undescended Testicle Market Insights
- According to Reed Intelligence analysis, the United States Undescended Testicle Market size was USD 574.62 Million in 2025 and is projected to reach USD 1015.38 Million by 2034.
- The United States market is projected to grow at a CAGR of 6.53% between 2026 and 2034.
- By segment, Surgical Treatment emerged as the largest Treatment Type in terms of market size in 2025.
- Surgical Treatment is anticipated to remain the most attractive Treatment Type segment, recording the fastest growth during the forecast period.
![United States Undescended Testicle Market Size, Share & Growth Analysis By [2034]](https://reedintelligence.com/uploads/charts/united-states-undescended-testicle-market-united-states-treatment-type-143249.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2025, United States held 26% of the global Undescended Testicle Market size.
- By 2034, United States is anticipated to capture the largest share of the global Undescended Testicle Market.
- In North America, United States is expected to lead the regional Undescended Testicle Market size by 2034.
- Canada will remain the fastest-growing market in North America, reaching USD 339.31 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 574.62 Million |
| Market Size In 2034 | USD 1015.38 Million |
| Largest segment | Surgical Treatment |
| Units | Revenue in USD Million |
| CAGR | 6.53% (2026-2034) |
| Segmnetation Covered | |
| Treatment Type |
|
| Diagnosis Method |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Undescended Testicle Market Treatment Type 2026-2034 (USD Million)
| Treatment Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical Treatment | XX.x | XX.x | XX.x | 361.95 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hormonal Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Undescended Testicle Market Diagnosis Method 2026-2034 (USD Million)
| Diagnosis Method | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical Examination | XX.x | XX.x | XX.x | 284.72 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ultrasound Imaging | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| MRI | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Undescended Testicle Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 261.8 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Pediatric Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.